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questionnaires were administered pre- and post-interven-
tion to 126 heart-failure patients within a randomized
controlled trial at a university-affiliated teaching center
with a referral base of HF patients.
RESULTS: The internal consistency of the EMA was
0.79 (Cronbach’s alpha). The internal consistency of the
MKA was 0.61 and the responsiveness was 0.75.
CONCLUSIONS: The availability of instruments, such
as those we have developed, can assist heart-failure pro-
grams to evaluate the impact of their educational inter-
ventions on knowledge gained, which will hopefully
translate into better patient outcomes.
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OBJECTIVE: Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure V
(1993) and VI (1997) recommend diuretics and beta-
blockers as initial antihypertensive drugs. However, a
few studies have shown a trend of increasing use of an-
giotensin-converting enzyme inhibitors (ACEIs) and cal-
cium channel blockers (CCBs), and decreasing use of di-
uretics and beta-blockers. The purpose of the study was
to examine the impact of insurance types on patterns of
antihypertensive drug use.
METHODS: A logistic regression model was employed
to examine whether insurance type was associated with
patterns of antihypertensive drug use by using Medical
Expenditure Panel Survey (MEPS, 1996), after control-
ling for confounding variables. The estimated study pop-
ulation enrolled was 10,357,769 non-institutionalized
adult US patients with essential hypertension.
RESULTS: Patients with HMO insurance were less likely
to use diuretics or beta-blockers (OR  0.499, 95%CI:
0.323-0.770), compared with the patients with fee-for-
service (FFS) insurance. Black patients were less likely to
use diuretics or beta-blockers compared with white pa-
tients (OR  0.577, 95%CI: 0.346-0.961). Compared
with non-married patients, married patients were 92 per-
cent more likely to use diuretics or beta-blockers (OR 
1.92, 95%CI: 1.299-2.838). Finally, patients diagnosed
between 1988 and 1992, and after 1993 were less likely
to use diuretics or beta-blockers (OR  0.486, 95%CI:
0.289-0.817; OR  0.416, 95%CI: 0.251-0.691), com-
pared with patients who were diagnosed with hyperten-
sion before 1988.
CONCLUSION: Insurance types are associated with the
patterns of antihypertensive drug use. Patients with
HMO insurance used more ACEIs or CCBs than patients
with FFS insurance. Further research is required to dis-
cern the reasons for the impact of insurance types so that
policy makers can propose efficient intervention.
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Pharmacists, as easily accessible health-care professionals
and advisors to the general public, are distributors of in-
formation and dispensers of health-care products. The
“French Consensus Conference on Smoking Cessation” –
(October 1998), summed up the aims of pharmacists in
helping smoking cessation as follows: lead by example;
enforce smoking bans in pharmacies; underline the signif-
icant risks linked to cigarette smoking; encourage non
smoking; advise, aid and monitor the smoker who has
decided to stop smoking.
OBJECTIVE: To measure the progress of the French
Pharmacist’s Smoking Cessation Program.
METHODS: The STOP program, through a question-
naire distributed to approximately 2500 pharmacists,
aims at describing the progress pharmacists are making
with regard to their own tobacco dependence as well as
in the public health initiative entrusted to them.
RESULTS: Here we present the preliminary results of
this investigation, through the analysis of the first 300
questionnaires. The average age of our sample popula-
tion was 46 years, 55 % were male. 67% had attended a
smoking cessation course. Ninety percent of these at-
tended a course given by the pharmaceutical industry,
and 7% attended a course given by an anti-smoking or-
ganization. Ninety eight percent of the pharmacists that
replied offered information on aiding smoking cessation,
either through window displays(67%) or displays in the
pharmacy (70 %). After delivering a nicotine substitute,
80% of pharmacists do not arrange a follow-up appoint-
ment. This lack of follow-up is explained on the part of
the client by lack of motivation (48%) and clients not re-
turning to the same pharmacy (34%). For the pharmacist
the main reason is the absence of adequate follow-up
tools (54%).
CONCLUSION: Since the delisting of nicotine substi-
tutes, pharmacists have played a major role in their deliv-
ery and should therefore play a strategic role in the fight
against tobacco dependence.
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Over half of regular consumers of tobacco, including
many young people state a desire to break from tobacco
dependence, but very few succeed in the long term.
OBJECTIVES: The objectives of the program can be
summed up as follows: to contribute to improving public
health knowledge; to understand the progress made by
smokers and ex-smokers; to anticipate success factors in
smoking cessation.
METHODS: In May 2001, 5000 user questionnaires
were distributed by GPs and pharmacists to smokers (S)
or ex-smokers (ES). The questionnaire included the most
frequently used tests, a socio-demographic profile, the in-
dividual’s smoking experience and a questionnaire of
knowledge of the smoking environment.
RESULTS: Presented here is the outcome of the analysis of
the first 700 responses, permitting a better understanding
of how smokers progress when they break from tobacco
dependence. The male/female ratio between smokers
(42%/58%) and ex-smokers (57%/43%) is statistically
significant (p  0.01), both for age (S/ES  39/46yrs) and
weight (S/ES  66/71kg). Forty three percent of ES said
they had a regular sporting activity as opposed to 26% of
S (p  0.001). The daily consumption of a cup of coffee
was different (S/ES  4.1/2.7) (p0.0001). There was no
difference with respect to alcohol consumption. Both
groups complained of being exposed to passive smoke:
S/ES  44%/41%. Forty-seven percent of the smokers
said they had a history of depressive problems, as opposed
to 36% of the former smokers p  0.02.
CONCLUSION: These first results confirm the growing
proportion of women who are tobacco dependent, the in-
fluence of passive smoking and the progress of the
smoker when he or she becomes an ex-smoker.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (Actos *NF) in combination therapy for patients
with type 2 diabetes in Finland.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics (Palmer et al., 2000) was
adapted to simulate long-term (80 years or until death)
management, health outcomes, resource utilisation and
treatment costs of patients with type2 diabetes. The
model accounts for most complications occurring in dia-
betes patients: nephropathy; retinopathy; acute myocar-
dial infarction; angina pectoris; stroke, and amputation.
The analysis was done from third-party-payer perspective
and costs figured relative to the year 2000. A 5% dis-
count rate was applied to costs and outcomes and sensi-
tivity analysis was performed to test the results.
RESULTS: Pioglitazone (PIO) 30 mg and metformin
(MF) were associated with longer life expectancy (15.16
years) than sulphonylureas (SU)/MF (14.47) or rosiglita-
zone (RSG) 8 mg/MF (15.06). PIO 30 mg/SU and PIO15
mg/SU are associated with the lowest number of serious
complications per 100 patients treated. For every 21 pa-
tients treated with PIO 30 mg/MF rather than SU/MF or
every 41 patients, respectively, for PIO15 mg/SU rather
MF/SU one complication is avoided. Combinations of
PIO 30 mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are as-
sociated with lower mortality than the other treatment
combinations available. Thus, for every 35 patients
treated with PIO 30 mg/MF rather than SU/MF one
death will be avoided after 15 years of treatment.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and may
represent a cost-effective use of scarce resources. It is nec-
essary to confirm the results of this theoretical model
once long-term effectiveness data with the compared al-
ternatives are available.
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OBJECTIVE: We assessed the incidence of diabetes in an
ambulatory population treated for the first time with ei-
ther olanzapine or risperidone.
METHODS: We conducted a population-based cohort
study using data from the Quebec drug benefit plan. In-
cluded in the cohort, all people who received a first pre-
scription of olanzapine or risperidone between 1/1/1997
and 8/31/1999, who were eligible for the drug plan, had
not been prescribed an antidiabetic drug or any atypical
antipsychotic for the six-month period preceding the first
olanzapine or risperidone prescription. Person-months of
follow-up were calculated as the amount of time from the
date of the first olanzapine or risperidone prescription to
the date of the first antidiabetic drug prescription. Those
who had a prescription for an antidiabetic drug were
considered as having diabetes. Subjects who discontinued
olanzapine or risperidone, who became non-eligible for
the drug plan and those who reached the end of the fol-
low-up period (8/31/2000) were censored at the event
date. We used a proportional hazard model to compute
the age- and sex-adjusted incidence-rate ratio (IRR) of
having diabetes among olanzapine users compared to ris-
peridone users.
